HOME >> MEDICINE >> NEWS
Tamoxifen reduces risk of breast cancer, follow-up study confirms

Data from additional years of follow-up of a large randomized placebo-controlled clinical trial of tamoxifen for the prevention of breast cancer confirm that the drug reduces the risk of invasive and noninvasive breast cancer, according to a report that appears in the November 16 issue of the Journal of the National Cancer Institute.

The National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (P-1) began in 1992. More than 13,000 women aged 35 years and older who were at high risk for breast cancer were randomly assigned to receive either a placebo or tamoxifen for 5 years. In 1998, the study's independent data monitoring committee recommended that the study be unblinded. An overall 49% reduction in breast cancer risk was observed in women taking tamoxifen. Participants were informed of whether they were taking a placebo or tamoxifen so that women who were taking placebo could be given the option to take tamoxifen.

The initial findings from the study--which appeared in the Sept. 16, 1998, issue of the Journal of the National Cancer Institute--indicated that tamoxifen reduced the risk of invasive and noninvasive breast cancer. Tamoxifen was also found to reduce the risk of osteoporotic fractures but to increase the risks of endometrial cancer and thromboembolism.

In their follow up study, Bernard Fisher, M.D., and colleagues have updated the P 1 data. They found that, after 7 years of follow-up, the cumulative rate of invasive breast cancer was reduced by 43%, from 42.5 cases per 1,000 women in the placebo group to 24.8 cases per 1,000 women in the tamoxifen group. The rate of noninvasive breast cancer was reduced by 37%, from 15.8 cases per 1,000 women in the placebo group to 10.2 cases per 1,000 women in the tamoxifen group. The risks of stroke, deep-vein thrombosis, cataracts, ischemic heart disease, and death were similar to what was reported in 1998. The risk of pulmonary embolism was abou
'"/>

Contact: Kate Travis
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
15-Nov-2005


Page: 1 2

Related medicine news :

1. Tamoxifen discontinuation rates surprisingly high in clinical practice
2. Tamoxifen for breast cancer prevention does not benefit most women
3. Tamoxifen shows no benefit, risk for breast cancer survivors heart health
4. Tamoxifen can reduce breast pain in prostate cancer patients
5. Nonhormonal drug reduces hot flashes in men treated for prostate cancer
6. Circumcision reduces HIV infection risk
7. Retinol lotion reduces the fine wrinkles from natural aging of skin
8. Improving communication with families of dying patients reduces stress, anxiety and depression
9. New study: Pycnogenol reduces heart failure
10. Drinking farm milk reduces childhood asthma and allergies but raw consumption remains unsafe
11. Angioplasty reduces long-term cardiac risk among heart patients with silent ischemia

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2019)... ... February 13, 2019 , ... Following the longest federal government ... American Academy of Sleep Medicine (AASM) is warning that such shutdowns exacerbate the ... Transportation Security Administration (TSA) officers. , “Even in typical circumstances, safety may be ...
(Date:2/13/2019)... , ... February 13, 2019 , ... ... 2019, at the company’s annual member conference, Elevate 2019 at the Gaylord Rockies ... staff and members to explore potential partnerships driving improved quality of patient care, ...
(Date:2/13/2019)... ... ... Castle announced today that it has raised $9.2M in Series A funding ... First Round and F-Prime Capital Partners . Angel investors joining the ... Alto Networks, and Olivier Pomel, CEO at Datadog. This round brings the company’s total ...
(Date:2/13/2019)... ... February 13, 2019 , ... Dr. Jig Patel and the ... Merchant, an exceptionally talented and knowledgeable dentist from St. Louis, MO, to ... techniques, such as CEREC same-day dentistry, root canals and emergency treatment. Dr. Patel, Dr. ...
(Date:2/13/2019)... ... 2019 , ... Surgery that moves both jaws forward – known as maxillomandibular ... (OSA), resulting in benefits that include improved breathing, daytime wakefulness and quality of life, ... should be regarded as the preferred treatment for patients with moderate to severe OSA ...
Breaking Medicine News(10 mins):
(Date:2/13/2019)... ... February 13, 2019 , ... The Louisville Men’s Clinic has ... of 2013 and, to date, has been visited by over 20,000 men suffering ... 90% success rate, The Louisville Men’s Clinic prides itself on being on the ...
(Date:2/13/2019)... , ... February 13, 2019 , ... ... innovation expert, will deliver the keynote speech on Wednesday, May 8, at its ... May 6-8 at the Westin Kierland Resort & Spa in Scottsdale, Arizona, and ...
(Date:2/13/2019)... ... February 13, 2019 , ... IMAT Solutions, a ... is launching IMAT 8.0, its latest health data platform, at HIMSS 2019. , ... interface and dynamic single-query builder, IMAT 8.0 allows HIEs, payers, hospitals, clinics, and ...
Breaking Medicine Technology:
Cached News: